Clinical and Demographic Features of Dementia with Lewy bodies patients, Alzheimer’s Disease Patients at the stage of MCI or prodromal and dementia, and healthy elderly controls.

<p>^a Mean (standard deviation).</p><p>^bEducation: 1 = before High School, 2 = High School, 3 = University.</p><p>^c As rated on Unified Parkinson's Disease Rating Scale¹⁵.</p><p>^dPercentage.</p><p>^e Mean (standard deviation, number of patients tested).</p><p>^f according to Scheltens et al.,JNNP, 1992.</p><p>^<b>g</b>Tukey post-hoc test for ANOVA (F), Mann-Whitney post-hoc test on SPSS (H). CAF = Clinician Assessment of Fluctuation; CDR = Clinical Dementia Rating; ChEI = CholinEsteraseInhbitor; Dopa = L-Dopa or dopaminergic agonists; MMSE = Mini-Mental Status Examination; NL = Neuroleptics (only clozapin or quetiapin); N = number; RBD = Rapid Eye Movement sleep Behaviour Disorder; TMTA = Trail Making Test A; TMTB = Trail Making Test B; UPDRS = Unified Parkinson's Disease Rating Scale.</p><p>Clinical and Demographic Features of Dementia with Lewy bodies patients, Alzheimer’s Disease Patients at the stage of MCI or prodromal and dementia, and healthy elderly controls.</p

Cortical thinning patterns in pro-DLB, pro-AD, DLB-d and AD-d compared to healthy older controls (A = Anterior, P = Posterior, FDR = False Discovery Rate).

<p>Cortical thinning patterns in pro-DLB, pro-AD, DLB-d and AD-d compared to healthy older controls (A = Anterior, P = Posterior, FDR = False Discovery Rate).</p

Location and peak vertex significance of cortical thinning in pro-DLB, DLB-d, pro-AD and AD-d compared to healthy subjects as well as pro-DLB relative to pro-AD, and DLB-d compared to AD-d.

<p>Table depicts anatomical region, FreeSurferTalairach coordinates, number of vertices within each cluster (NVtxs), surface area (Area) (mm2) and peak significance expressed as a—log10P value (e.g.,-log10P = 3 corresponds to p = 0.001…etc). All results are significant (p<0.05 FDR corrected) except where noted by asterisk (*) which were uncorrected.</p><p>Location and peak vertex significance of cortical thinning in pro-DLB, DLB-d, pro-AD and AD-d compared to healthy subjects as well as pro-DLB relative to pro-AD, and DLB-d compared to AD-d.</p

Flow Chart of the present study on cortical thickness in prodromal and dementia stages of Lewy body dementia and Alzheimer's disease.

<p>AD = Alzheimer’s disease; DLB = Dementia with Lewy bodies; MCI = Mild Cognitive Impairment. Prodromal DLB means patients with McKeith's criteria of DLB with cognitive impairment but without dementia. Psychiatric pathologies included two patients with depression, one with bipolar disorder, and one histrionic personality disorder; and one cognitive impairment due to severe sleep apnoea, one vitamin B12 encephalopathy, and one mitochondriopathy for patients with MCI. Other brain pathologies included one Parkinson's disease dementia, one DLB with primary Sjögren's syndrome, one with chronic brain autoimmune encephalitis and one dementia without evolution for more than 10 years, for patients with dementia</p

Patterns of Cortical thinning between Pro-AD and Pro-DLB and between AD-d and DLB-d (A = Anterior, P = Posterior, FDR = False Discovery Rate).

<p>Patterns of Cortical thinning between Pro-AD and Pro-DLB and between AD-d and DLB-d (A = Anterior, P = Posterior, FDR = False Discovery Rate).</p

Are consumption of dairy products and physical activity independently related to bone mineral density of 6-year-old children? Longitudinal and cross-sectional analyses in a birth cohort from Brazil

Objective: To evaluate cross-sectional and longitudinal associations of consumption of dairy products and physical activity (PA) with bone mineral density (BMD). Design: Cohort study with children from the 2004 Pelotas (Brazil) Birth Cohort. Setting: Pelotas, a medium-sized Brazilian city. Subjects: The study started in 2004 and mothers/children were interviewed/measured periodically from birth to age 6 years. PA was measured by maternal proxy at 4 and 6 years and by accelerometry at 6 years. Consumption of dairy products was measured using 24 h food recall (at 4 years) and FFQ (at 6 years). Total-body and lumbar-spine BMD (g/cm2) were measured by dual-energy X-ray absorptiometry. Results: At 6 years, BMD was measured in 3444 children and 2636 children provided data on objectively measured PA by accelerometry. Consumption of dairy products at 4 years was associated with higher lumbar-spine BMD at 6 years in boys, while current consumption was positively associated with BMD in both sexes (P < 0·001). PA assessed by maternal report at 4 and 6 years of age was associated with higher BMD at 6 years in boys. PA assessed by accelerometry was positively related to total-body and lumbar-spine BMD in boys and lumbar-spine BMD in girls. We did not find evidence for an interaction between PA and consumption of dairy products on BMD. Conclusions: We observed positive and independent longitudinal and cross-sectional associations between consumption of dairy products and PA with BMD in the total body and at the lumbar spine in young children

MOESM1 of Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara

Additional file 1. Raw data set of the IgG and GIA responses for the phase 1 trial of PfAMA1 FVO [25-545] in Malians adults in Bandiagara